JPRN-UMIN000003499
Recruiting
Phase 2
Phase II clinical trial of low dose dasatinib in patients with resistant or intolerant chronic myeloid leukemia who are treated with low lose imatinib - A study of low dose dasatinib in patients with resistant or intolerant CML who are treated with low lose imatinib
Kanto CML Study Group0 sites30 target enrollmentApril 20, 2010
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Chronic myeloid leukemia patients in chronic phase who are refractory or resistant to low dose imatinib therapy.
- Sponsor
- Kanto CML Study Group
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Exclusion Criteria: Concurrent malignancy other than CML Women who are pregnant or breastfeeding Concurrent pleural effusion Uncontrolled or significant cardiovascular disease A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy. Prior therapy with dasatinib Subjects with T315I and/or F317L BCR\-ABL point mutations
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II clinical trial of dasatinib in newly diagnosed chronic phase chronic myelogenous leukemianewly diagnosed chronic myelogenous leukemia in chronic phaseJPRN-UMIN000006346Ph leukemia trial Group50
Active, not recruiting
Not Applicable
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-GBEBMT (European group for Blood and Marrow Transplantation)50
Active, not recruiting
Not Applicable
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow TransplantatioEUCTR2008-001361-29-FREBMT (European group for Blood and Marrow Transplantation)50
Active, not recruiting
Not Applicable
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-DEEBMT (European group for Blood and Marrow Transplantation)50
Completed
Phase 2
Phase II clinial trial of Dasatinib for Imatinib resistant or refractory chronic myeloid leukemia in chronic phase.Chronic myeloid leukemia patients in chronic phase who are refractory or resistant to Imatinib therapy.JPRN-UMIN000002779Ph Leukemia Trial Group120